Anaptysbio (ANAB) Share-based Compensation (QoQ) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Anaptysbio | 1.60 Bn | 1.31 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 67.15% |
| Dec 31, 2025 | -7.11% |
| Sep 30, 2025 | -0.89% |
| Jun 30, 2025 | 0.75% |
| Mar 31, 2025 | 12.05% |
| Dec 31, 2024 | -0.06% |
| Sep 30, 2024 | 8.55% |
| Jun 30, 2024 | -25.54% |
| Mar 31, 2024 | 24.90% |
| Dec 31, 2023 | 170.37% |
| Sep 30, 2023 | 3.45% |
| Jun 30, 2023 | -67.27% |
| Mar 31, 2023 | 32.54% |
| Dec 31, 2022 | 122.83% |
| Sep 30, 2022 | 3.45% |
| Jun 30, 2022 | -62.54% |
| Mar 31, 2022 | 94.62% |
| Dec 31, 2021 | -8.85% |
| Sep 30, 2021 | 18.27% |
| Jun 30, 2021 | 11.31% |
| Mar 31, 2021 | 11.32% |
| Dec 31, 2020 | 6.17% |
| Sep 30, 2020 | 2.33% |
| Jun 30, 2020 | -7.87% |
| Mar 31, 2020 | 7.91% |
| Dec 31, 2019 | -12.31% |
| Sep 30, 2019 | -13.70% |
| Jun 30, 2019 | 27.07% |
| Mar 31, 2019 | 9.39% |
| Dec 31, 2018 | 3.52% |
| Sep 30, 2018 | -0.63% |
| Jun 30, 2018 | 12.74% |
| Mar 31, 2018 | 99.65% |
| Dec 31, 2017 | 20.17% |
| Sep 30, 2017 | -34.49% |
| Jun 30, 2017 | 66.05% |
| Mar 31, 2017 | 200.69% |
| Dec 31, 2016 | 12.94% |
| Sep 30, 2016 | -13.56% |
| Jun 30, 2016 | -8.39% |